Investigational drug · Phase 2
LM103 TILs
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Melanoma, Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "LM103 TILs"
First trial start
2025
Dec 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LM103 TILs", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Melanoma
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LM103 TILs" as an intervention, largest first.
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT07310784 · 92 participants (planned) · Start Dec 16, 2025 · Primary completion Dec 31, 2027
Drug: LM103 TILs Injection; Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin · For: Advanced Melanoma
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 16 sites in all
- A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung CancerRecruiting
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT07444437 · 45 participants (planned) · Start Feb 26, 2026 · Primary completion Dec 31, 2027
Drug: LM103 TILs Injection; PD-1 / PD-L1 monoclonal antibody · For: Non-Small Cell Lung Cancer
Sites: Guangzhou, China; Zhengzhou, China; Chengdu, China · 5 sites in all
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT05971576 · 20 participants (planned) · Start Aug 2023 · Primary completion Apr 2026
Drug: LM103 · For: Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT05366478 · 15 participants (planned) · Start May 30, 2022 · Primary completion May 30, 2024
Drug: Autologous tumor infiltrating lymphocytes (TILs) · For: Melanoma; Non Small Cell Lung Cancer; Cervical Carcinoma
Sites: Tianjin, China
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT05971589 · 5 participants (planned) · Start Aug 2023 · Primary completion Apr 2026
Drug: LM103 · For: Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.Industry
NCT05941936 · 5 participants (planned) · Start May 19, 2023 · Primary completion Feb 2025
Drug: LM103 · For: Solid Tumor
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Melanoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
- BrenetafuspIMC-F106CPhase 32 trials
Immunocore Ltd · Select Advanced Solid Tumors, Advanced Melanoma
- RO7198457Autogene CevumeranPhase 24 trials
Roche (Genentech) · Colorectal Cancer Stage II, Colorectal Cancer Stage III, Adenocarcinoma, Pancreatic Ductal
- T3011Phase 24 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor
- OPM-101Phase 21 trial
Oncodesign Precision Medicine · Advanced Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.